NIH Awards VBI, Mayo Clinic $2.4M To Study Chronic Rhinosinusitis

[Guest guest]

_http://www.medicalnewstoday.com/medicalnews.php?newsid=70272 & nfid=nl#ratethis

_

(http://www.medicalnewstoday.com/medicalnews.php?newsid=70272 & nfid=nl#ratethis)

NIH Awards VBI, Mayo Clinic $2.4M To Study Chronic Rhinosinusitis

Main Category: _Ear, Nose and Throat News_

(http://www.medicalnewstoday.com/sections/ent/)

Article Date: 12 May 2007 - 23:00 PDT

(http://www.medicalnewstoday.com/sections/allergy/)

(http://www.medicalnewstoday.com/newsletters.php)

(http://www.medicalnewstoday.com/newsalerts.php)

Virginia Bioinformatics Institute and Virginia Tech biological sciences

associate professor Lawrence is teaming up with Mayo Clinic on a $2.4

million project funded by the National Institute of Allergy and Infectious

Diseases (NIAID). The work could help researchers develop treatments,

diagnostic

tools, and preventative measures for patients suffering from chronic

rhinosinusitis (CRS).

CRS is a debilitating chronic airway disease that results in up to 18 - 22

million clinical cases per year and at least 30 million courses of antibiotic

treatment (National Center for Health Statistics). CRS can produce

inflammation of the lining of the nasal sinus. In some cases, this is followed

by

thickening of sinus mucosa and the formation of polyps or growths in the nasal

cavity. Even with aggressive medical and surgical therapies, a significant

number of patients with CRS have persistent or recurrent problems associated

with

the disease. The goal of the five-year project, entitled " The Pathogenesis of

Chronic Rhinosinusitis, " is to positively impact treatment, clinical

decisions, and medical care costs involving CRS, as well as develop a better

understanding of the mechanisms of the disease.

Dr. Lawrence, associate professor at VBI, stated: " Several years ago

researchers at Mayo, including clinical assistant professor Jens Ponikau, who

is now at the University at Buffalo School of Medicine & Biomedical Sciences,

and Hirohito Kita, professor of Immunology and the director of the Allergic

Diseases Laboratory at Mayo, discovered that lymphocytes including T-cells

from a significant percentage of CRS patients have an overzealous inflammatory

immune response to antigens derived from common airborne fungi. The most

exaggerated and statistically significant response by far was to Alternaria

alternata antigens

************************************** See what's free at http://www.aol.com.

[Guest guest]

Thanks Sharon, glad they are looking further into CRS. I thought they

described their fingings back in 99 as fungus being involved in

sinusitis as in allergic fungal sinusitis. I recall a article I read

about the difference in AFS and CRS and there was a difference in the

amount of 2 types of T-helper cells found. cant remember at the

moment but know one is found more with allergy responce and the other

with toxic or irritant responce. my mcs testing showed level 3-

cytotoxic with alternaria. and found that it grows year around here

and I fight sinus problems year around too. the mayo clinic did

dignose me with CRS when there in 2003. added up I know this mold is

one thats a major problem for me. noticed they didn't really say it

was a allergic reaction but pathogenic.

>

> _http://www.medicalnewstoday.com/medicalnews.php?

newsid=70272 & nfid=nl#ratethis

> _

> (http://www.medicalnewstoday.com/medicalnews.php?

newsid=70272 & nfid=nl#ratethis)

>

>

> NIH Awards VBI, Mayo Clinic $2.4M To Study Chronic Rhinosinusitis

> Main Category: _Ear, Nose and Throat News_

> (http://www.medicalnewstoday.com/sections/ent/)

> Article Date: 12 May 2007 - 23:00 PDT

>

>

> (http://www.medicalnewstoday.com/sections/allergy/)

>

>

>

> (http://www.medicalnewstoday.com/newsletters.php)

> (http://www.medicalnewstoday.com/newsalerts.php)

>

>

>

> Virginia Bioinformatics Institute and Virginia Tech biological

sciences

> associate professor Lawrence is teaming up with Mayo Clinic

on a $2.4

> million project funded by the National Institute of Allergy and

Infectious

> Diseases (NIAID). The work could help researchers develop

treatments, diagnostic

> tools, and preventative measures for patients suffering from

chronic

> rhinosinusitis (CRS).

>

> CRS is a debilitating chronic airway disease that results in up to

18 - 22

> million clinical cases per year and at least 30 million courses of

antibiotic

> treatment (National Center for Health Statistics). CRS can produce

> inflammation of the lining of the nasal sinus. In some cases, this

is followed by

> thickening of sinus mucosa and the formation of polyps or growths

in the nasal

> cavity. Even with aggressive medical and surgical therapies, a

significant

> number of patients with CRS have persistent or recurrent problems

associated with

> the disease. The goal of the five-year project, entitled " The

Pathogenesis of

> Chronic Rhinosinusitis, " is to positively impact treatment,

clinical

> decisions, and medical care costs involving CRS, as well as develop

a better

> understanding of the mechanisms of the disease.

>

> Dr. Lawrence, associate professor at VBI, stated: " Several

years ago

> researchers at Mayo, including clinical assistant professor Jens

Ponikau, who

> is now at the University at Buffalo School of Medicine &

Biomedical Sciences,

> and Hirohito Kita, professor of Immunology and the director of the

Allergic

> Diseases Laboratory at Mayo, discovered that lymphocytes including

T-cells

> from a significant percentage of CRS patients have an overzealous

inflammatory

> immune response to antigens derived from common airborne fungi.

The most

> exaggerated and statistically significant response by far was to

Alternaria

> alternata antigens

>

>

>

> ************************************** See what's free at

http://www.aol.com.

>

>

>